RxDoctor Payments Data

Dianolis Trinidad

Cardiovascular Disease · Bayamon, PRNPI 1104986322

Payments from drug & device makers

$2,144in general payments, 2019–2025

Across 66 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$438
  • Amgen$370
  • E.r. Squibb & Sons, L.L.C.$318
  • PBG Puerto Rico LLC$245
  • Boston Scientific$234
  • AstraZeneca$206
  • plus $333 from 4 others

What the payments were for

  • Food & beverage$2,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson13$438
Amgen7$370
E.r. Squibb & Sons, L.L.C.9$318
PBG Puerto Rico LLC11$245
Boston Scientific3$234
AstraZeneca10$206
Medtronic(2 entities)2$143
Boehringer Ingelheim4$95
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$55
Pfizer Pharmaceuticals LLC2$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,144 in reported general payments places this provider in the 40th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,426
Medicare patients
15
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$150,255
XareltoRivaroxaban40$50,283
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid99$18,203
Candesartan Cilexetil121$18,111
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid72$9,413
FarxigaDapagliflozin Propanediol11$8,803
Metoprolol Succinate372$8,602
Omega-3 Acid Ethyl Esters157$8,188
Rosuvastatin Calcium431$7,972
Ezetimibe277$7,503
Irbesartan200$6,795
Atorvastatin Calcium489$6,338
Diovan HctValsartan/Hydrochlorothiazide12$5,912
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide105$4,306
Nifedipine ErNifedipine109$3,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$438$50,28340 claims
AstraZenecaFarxiga$206$8,80311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →